Is intrathecal or intraventricular therapy with polymyxins or aminoglycosides still needed for improving the outcome of post-neurosurgical extensively/multi drug-resistant (XDR/MDR) Gram-negative bacteria (-GNB) related meningitis/ventriculitis in the current era of novel beta-lactams beta-lactam/beta-lactamase inhibitor combinations?